Aditya Tedjaseputra
YOU?
Author Swipe
View article: FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials
FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials Open
Introduction In NPM1 mutant AML, detection of measurable residual disease by reverse transcription quantitative PCR (hereafter, NPM1 MRD) in peripheral blood (PB) after two cycles of intensive chemotherapy (PC2) identifies patients at high…
View article: Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML
Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML Open
Despite the use of FLT3 inhibitors, outcomes for patients with FLT3 mutated (FLT3mut) AML remain suboptimal because of high rates of relapse. We evaluated the safety and efficacy of the combination of daunorubicin, cytarabine (DA), gemtuzu…
View article: Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse Open
Background Next generation sequencing (NGS) of cell free tumour DNA (ctDNA) provides a snapshot of lymphoma mutations correlating with tumour burden. We evaluated the ability of ctDNA to molecularly profile and track disease burden in pati…
View article: 23 | RADIOTHERAPY IMPROVES PROGRESSION‐FREE SURVIVAL FOR STAGE IA NLPHL: A RETROSPECTIVE REPORT FROM THE GLOBAL NLPHL ONE WORKING GROUP (GLOW)
23 | RADIOTHERAPY IMPROVES PROGRESSION‐FREE SURVIVAL FOR STAGE IA NLPHL: A RETROSPECTIVE REPORT FROM THE GLOBAL NLPHL ONE WORKING GROUP (GLOW) Open
View article: International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: Responses
International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: Responses Open
View article: International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: Summary
International Forum on the Use of Irradiated Blood in Patients With Haematological Malignancy: Summary Open
View article: Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach Open
Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach…
View article: SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia
SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia Open
Molecular measurable residual disease (MRD, eg, by real-time quantitative polymerase chain reaction, RT-qPCR), is an integral part of response assessment in acute myeloid leukemia (AML) with established prognostic and evolving therapeutic …
View article: Candida parapsilosis bone marrow infection in an immunocompetent patient
Candida parapsilosis bone marrow infection in an immunocompetent patient Open
Our case seeks to demonstrate a novel case whereby a bone marrow aspirate culture provided a conclusive diagnosis of invasive Candida parapsilosis bone marrow infection, and guided treatment in an immunocompetent patient. It is impo…
View article: Day-21 bone marrow morphology in patients with FLT3-mutated AML incorrectly designates persistent leukaemia
Day-21 bone marrow morphology in patients with FLT3-mutated AML incorrectly designates persistent leukaemia Open
View article: International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma Open
View article: Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation Open
View article: Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry
Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry Open
Background Lymphoma is a malignancy of lymphocytes and lymphoid tissues comprising a heterogeneous group of diseases, with up to 80 entities now described. Lymphoma is the 6 th most common cancer in Australia, affecting patients of all age…
View article: Clinical impact of <i>NPM1</i>-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Clinical impact of <i>NPM1</i>-mutant molecular persistence after chemotherapy for acute myeloid leukemia Open
Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persisten…
View article: Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated with <i>BRAF</i> V600E mutation
Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated with <i>BRAF</i> V600E mutation Open
Acute monocytic leukaemia (French-British-American classification: AML-M5b) is characterised by a predominance of cells of the monocytic lineage on bone marrow examination. Furthermore, a discerning feature is its tendency for tissue infil…